CRANBURY, N.J.--(BUSINESS WIRE)--Nov. 21, 2005--Valera Pharmaceuticals announced today that its subsidiary company, Valera Pharmaceuticals Ireland Limited, received marketing authorization from the Danish Medicines Agency for VANTAS(TM), its 12-month implant for the palliative treatment of advanced prostate cancer.